| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinoblastoma | 15 | 2013 | 200 | 1.560 |
Why?
|
| Genetic Vectors | 9 | 2020 | 1694 | 1.070 |
Why?
|
| Adenoviridae | 8 | 2020 | 1459 | 1.050 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 13 | 1997 | 44 | 0.870 |
Why?
|
| Versicans | 2 | 2020 | 28 | 0.800 |
Why?
|
| Retinal Neoplasms | 7 | 2012 | 144 | 0.770 |
Why?
|
| Adenoviridae Infections | 1 | 2020 | 125 | 0.710 |
Why?
|
| Virus Replication | 2 | 2020 | 709 | 0.690 |
Why?
|
| Hyaluronan Receptors | 3 | 2020 | 249 | 0.640 |
Why?
|
| Photoreceptor Cells | 10 | 1996 | 75 | 0.590 |
Why?
|
| Proteolysis | 2 | 2020 | 370 | 0.530 |
Why?
|
| Antiviral Agents | 2 | 2020 | 1230 | 0.480 |
Why?
|
| Retinal Rod Photoreceptor Cells | 6 | 1997 | 84 | 0.480 |
Why?
|
| Corneal Transplantation | 1 | 2012 | 39 | 0.440 |
Why?
|
| Cyclic GMP | 6 | 1996 | 116 | 0.430 |
Why?
|
| Genetic Therapy | 8 | 2020 | 1616 | 0.420 |
Why?
|
| Transgenes | 2 | 2012 | 557 | 0.410 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 204 | 0.390 |
Why?
|
| Hyaluronic Acid | 3 | 2020 | 168 | 0.330 |
Why?
|
| Dog Diseases | 5 | 1997 | 73 | 0.330 |
Why?
|
| DNA, Viral | 3 | 2020 | 694 | 0.320 |
Why?
|
| Graft Rejection | 1 | 2012 | 834 | 0.320 |
Why?
|
| Phosphoric Diester Hydrolases | 5 | 1993 | 103 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 3230 | 0.260 |
Why?
|
| Gene Expression | 3 | 2012 | 3570 | 0.250 |
Why?
|
| COS Cells | 2 | 2017 | 377 | 0.250 |
Why?
|
| Retina | 8 | 2012 | 532 | 0.250 |
Why?
|
| Vitreous Body | 2 | 2020 | 123 | 0.250 |
Why?
|
| Oncolytic Viruses | 3 | 2013 | 204 | 0.240 |
Why?
|
| Rod Cell Outer Segment | 7 | 1991 | 46 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4757 | 0.200 |
Why?
|
| Picornaviridae | 2 | 2013 | 24 | 0.190 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 5 | 0.190 |
Why?
|
| Maleimides | 1 | 2020 | 22 | 0.190 |
Why?
|
| Metalloproteases | 1 | 2020 | 24 | 0.190 |
Why?
|
| Diamines | 1 | 2020 | 24 | 0.190 |
Why?
|
| Permeability | 1 | 2020 | 167 | 0.180 |
Why?
|
| Amides | 1 | 2020 | 123 | 0.180 |
Why?
|
| Dipeptides | 1 | 2020 | 91 | 0.180 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 85 | 0.180 |
Why?
|
| Hydroxyurea | 1 | 2020 | 204 | 0.180 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 280 | 0.170 |
Why?
|
| Cattle | 11 | 1997 | 783 | 0.170 |
Why?
|
| Animals | 33 | 2017 | 59536 | 0.160 |
Why?
|
| Protein Kinase C | 1 | 2020 | 396 | 0.160 |
Why?
|
| Conjunctiva | 1 | 2020 | 250 | 0.160 |
Why?
|
| Magnesium | 2 | 1995 | 160 | 0.160 |
Why?
|
| Hydroxamic Acids | 1 | 2020 | 442 | 0.150 |
Why?
|
| DNA, Recombinant | 1 | 2017 | 121 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2020 | 435 | 0.150 |
Why?
|
| HeLa Cells | 2 | 2020 | 1643 | 0.150 |
Why?
|
| Dogs | 5 | 1997 | 1155 | 0.150 |
Why?
|
| STAT Transcription Factors | 1 | 2017 | 79 | 0.150 |
Why?
|
| Lead | 2 | 1995 | 54 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 1290 | 0.150 |
Why?
|
| Retinitis Pigmentosa | 2 | 1996 | 79 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 339 | 0.140 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 280 | 0.140 |
Why?
|
| Janus Kinases | 1 | 2017 | 174 | 0.140 |
Why?
|
| Phenytoin | 1 | 1996 | 71 | 0.140 |
Why?
|
| Thiazoles | 1 | 2020 | 726 | 0.140 |
Why?
|
| Eye Proteins | 3 | 2012 | 269 | 0.140 |
Why?
|
| Retinal Degeneration | 4 | 2001 | 85 | 0.130 |
Why?
|
| Pineal Gland | 1 | 1995 | 50 | 0.130 |
Why?
|
| Vision, Ocular | 2 | 1994 | 157 | 0.130 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 247 | 0.130 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 1995 | 67 | 0.130 |
Why?
|
| Genes, Reporter | 1 | 2017 | 798 | 0.130 |
Why?
|
| Thymidine Kinase | 3 | 2010 | 193 | 0.130 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.120 |
Why?
|
| Adenoviruses, Human | 2 | 2005 | 181 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 14289 | 0.120 |
Why?
|
| Eye | 4 | 2010 | 301 | 0.120 |
Why?
|
| Kinetics | 8 | 1995 | 2049 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2012 | 1385 | 0.120 |
Why?
|
| Ion Channels | 2 | 1992 | 212 | 0.120 |
Why?
|
| Pyridines | 1 | 2020 | 1244 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 268 | 0.110 |
Why?
|
| Neoplasm Transplantation | 4 | 2011 | 1519 | 0.110 |
Why?
|
| Disease Models, Animal | 6 | 2013 | 7222 | 0.110 |
Why?
|
| Anticonvulsants | 1 | 1996 | 431 | 0.110 |
Why?
|
| Ganciclovir | 2 | 2005 | 174 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 1993 | 88 | 0.110 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2012 | 110 | 0.110 |
Why?
|
| Blotting, Western | 6 | 2010 | 3536 | 0.110 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 99 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2013 | 1008 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 1555 | 0.100 |
Why?
|
| Humans | 37 | 2020 | 261506 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2017 | 1271 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2012 | 253 | 0.100 |
Why?
|
| Neoplasms | 1 | 2017 | 15193 | 0.100 |
Why?
|
| Retinal Diseases | 1 | 1993 | 179 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2020 | 11965 | 0.090 |
Why?
|
| Phytohemagglutinins | 1 | 1990 | 71 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 362 | 0.090 |
Why?
|
| Antigen-Antibody Complex | 3 | 1985 | 115 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 238 | 0.090 |
Why?
|
| Choroid | 2 | 2006 | 35 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 1487 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2012 | 747 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 4 | 1988 | 276 | 0.080 |
Why?
|
| Transduction, Genetic | 2 | 2006 | 475 | 0.080 |
Why?
|
| Brain Neoplasms | 4 | 2013 | 4849 | 0.070 |
Why?
|
| Ureteroscopy | 1 | 2007 | 46 | 0.070 |
Why?
|
| Eye Enucleation | 2 | 2006 | 91 | 0.070 |
Why?
|
| Dextrans | 1 | 2007 | 90 | 0.070 |
Why?
|
| Mutation | 5 | 2013 | 15179 | 0.070 |
Why?
|
| Lymphocytes | 2 | 1990 | 1234 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 210 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1995 | 548 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2007 | 81 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.070 |
Why?
|
| Monocytes | 1 | 1990 | 788 | 0.070 |
Why?
|
| DNA Replication | 1 | 1990 | 744 | 0.070 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 66 | 0.070 |
Why?
|
| Optic Nerve | 1 | 2006 | 133 | 0.070 |
Why?
|
| Medulloblastoma | 1 | 2010 | 540 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 3101 | 0.060 |
Why?
|
| Electroretinography | 2 | 1996 | 116 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 1879 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2013 | 5395 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2005 | 716 | 0.060 |
Why?
|
| Child | 9 | 2020 | 29154 | 0.060 |
Why?
|
| Brain Diseases | 1 | 1988 | 403 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3154 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 14551 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 5 | 1995 | 4367 | 0.060 |
Why?
|
| Trypsin | 2 | 1996 | 140 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2004 | 157 | 0.060 |
Why?
|
| Vincristine | 1 | 1988 | 1511 | 0.060 |
Why?
|
| Egtazic Acid | 2 | 1995 | 54 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2359 | 0.060 |
Why?
|
| Glioma | 2 | 2013 | 1963 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2007 | 502 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 2796 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1443 | 0.050 |
Why?
|
| Mice | 14 | 2013 | 34495 | 0.050 |
Why?
|
| Seizures | 1 | 1988 | 989 | 0.050 |
Why?
|
| Immunosorbent Techniques | 2 | 1995 | 57 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 573 | 0.050 |
Why?
|
| Molecular Weight | 3 | 1990 | 629 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 115 | 0.050 |
Why?
|
| Calmodulin | 3 | 1990 | 241 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 1996 | 1764 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2003 | 191 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2001 | 203 | 0.050 |
Why?
|
| Cloning, Molecular | 3 | 1997 | 1213 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 332 | 0.040 |
Why?
|
| Cell Line | 5 | 2006 | 5114 | 0.040 |
Why?
|
| Infant | 8 | 2007 | 13310 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 1073 | 0.040 |
Why?
|
| Public Policy | 1 | 1999 | 60 | 0.040 |
Why?
|
| Rats | 4 | 2000 | 6086 | 0.040 |
Why?
|
| Calcium | 3 | 1995 | 1537 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1999 | 208 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 1997 | 869 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 1999 | 66 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2010 | 6150 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1990 | 82 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2013 | 1869 | 0.040 |
Why?
|
| Transducin | 1 | 1997 | 40 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2001 | 842 | 0.040 |
Why?
|
| Base Sequence | 5 | 1997 | 4917 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 1999 | 467 | 0.040 |
Why?
|
| Cell Separation | 1 | 1979 | 612 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 1997 | 6089 | 0.040 |
Why?
|
| Female | 11 | 2020 | 141928 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1999 | 604 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1993 | 264 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 1979 | 1294 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1997 | 4233 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2012 | 3033 | 0.030 |
Why?
|
| Codon | 2 | 1993 | 241 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 3869 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 1165 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 2 | 2010 | 284 | 0.030 |
Why?
|
| Blood Platelets | 2 | 1982 | 731 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 600 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1979 | 621 | 0.030 |
Why?
|
| Homozygote | 2 | 1997 | 717 | 0.030 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 2 | 1992 | 17 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 1996 | 148 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 568 | 0.030 |
Why?
|
| Reference Values | 1 | 1996 | 1099 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 1993 | 15 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 2013 | 86 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 3821 | 0.030 |
Why?
|
| United States | 2 | 2001 | 15433 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 293 | 0.030 |
Why?
|
| PAX6 Transcription Factor | 1 | 2012 | 53 | 0.030 |
Why?
|
| Thalassemia | 1 | 1992 | 26 | 0.030 |
Why?
|
| Globins | 1 | 1992 | 73 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2012 | 110 | 0.030 |
Why?
|
| Immune Sera | 2 | 1985 | 146 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2006 | 8223 | 0.030 |
Why?
|
| Luminescent Proteins | 2 | 2004 | 289 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 134 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1992 | 108 | 0.030 |
Why?
|
| Lizards | 1 | 1991 | 6 | 0.030 |
Why?
|
| Diltiazem | 1 | 1991 | 12 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1991 | 122 | 0.020 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1992 | 110 | 0.020 |
Why?
|
| Epitopes | 3 | 1984 | 685 | 0.020 |
Why?
|
| Isoenzymes | 2 | 1984 | 614 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2013 | 4078 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 2063 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 1990 | 5 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2004 | 694 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 1082 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 4 | 2006 | 6942 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 1990 | 249 | 0.020 |
Why?
|
| Heterozygote | 1 | 1993 | 1020 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 1992 | 335 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1984 | 1062 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 3981 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 1980 | 266 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1990 | 321 | 0.020 |
Why?
|
| Adolescent | 4 | 2020 | 31252 | 0.020 |
Why?
|
| Male | 10 | 2020 | 123000 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 2390 | 0.020 |
Why?
|
| Exons | 1 | 1992 | 1328 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 1471 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2001 | 5637 | 0.020 |
Why?
|
| Protein Conformation | 2 | 1997 | 1258 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1681 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1618 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 1979 | 171 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2007 | 16273 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 289 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1988 | 187 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 1143 | 0.020 |
Why?
|
| Phenotype | 3 | 1992 | 6295 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.020 |
Why?
|
| Necrosis | 1 | 2006 | 580 | 0.020 |
Why?
|
| Prednisone | 1 | 1988 | 984 | 0.020 |
Why?
|
| DNA | 1 | 1993 | 2693 | 0.020 |
Why?
|
| Membrane Cofactor Protein | 1 | 2004 | 10 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 38 | 0.020 |
Why?
|
| Integrin alphaV | 1 | 2004 | 20 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 882 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2013 | 9180 | 0.020 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1984 | 26 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4143 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1664 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3639 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 1304 | 0.010 |
Why?
|
| Myocardium | 1 | 1990 | 1313 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1391 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1984 | 266 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1982 | 31 | 0.010 |
Why?
|
| Pregnancy | 1 | 1996 | 7573 | 0.010 |
Why?
|
| Ear | 1 | 2001 | 38 | 0.010 |
Why?
|
| Sarcoma | 1 | 1992 | 1725 | 0.010 |
Why?
|
| Species Specificity | 2 | 1997 | 777 | 0.010 |
Why?
|
| Hydrolysis | 2 | 1995 | 227 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2001 | 104 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 122 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 2231 | 0.010 |
Why?
|
| Haplorhini | 1 | 2000 | 130 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 334 | 0.010 |
Why?
|
| Injections | 1 | 2001 | 285 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 1021 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 2292 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3552 | 0.010 |
Why?
|
| Integrins | 1 | 2001 | 262 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1979 | 88 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 7548 | 0.010 |
Why?
|
| Brain | 2 | 1990 | 4113 | 0.010 |
Why?
|
| Mice, Inbred C3H | 2 | 1992 | 385 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1979 | 256 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1979 | 225 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1979 | 185 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1979 | 139 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 4821 | 0.010 |
Why?
|
| Herpes Simplex | 1 | 1999 | 95 | 0.010 |
Why?
|
| Antigens | 1 | 1979 | 292 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1979 | 281 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 1489 | 0.010 |
Why?
|
| Prodrugs | 1 | 1999 | 217 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5112 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1979 | 471 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 1144 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1979 | 652 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 2314 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 7591 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1979 | 546 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 1033 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 2944 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 1016 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 997 | 0.010 |
Why?
|
| Lung | 2 | 1984 | 3151 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1979 | 966 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8865 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 553 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1979 | 1688 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 1586 | 0.010 |
Why?
|
| Muridae | 1 | 1992 | 21 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 128 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1992 | 13 | 0.010 |
Why?
|
| Centromere | 1 | 1992 | 97 | 0.010 |
Why?
|
| Poly A | 1 | 1992 | 87 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 354 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1988 | 7551 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1992 | 78 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 89 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1979 | 1960 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1992 | 250 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 294 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1991 | 220 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 2522 | 0.010 |
Why?
|
| Plasma | 1 | 1992 | 158 | 0.010 |
Why?
|
| Platelet Count | 1 | 1992 | 490 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1992 | 477 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1997 | 2483 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 17523 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 1999 | 5710 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 21713 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2007 | 37905 | 0.010 |
Why?
|
| Adult | 3 | 2007 | 77950 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 1005 | 0.000 |
Why?
|
| Immunotherapy | 1 | 2001 | 3341 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 10035 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 4938 | 0.000 |
Why?
|
| Time Factors | 1 | 2001 | 12926 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2007 | 32848 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1992 | 1819 | 0.000 |
Why?
|
| Anura | 1 | 1985 | 11 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 3203 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1988 | 15862 | 0.000 |
Why?
|
| Remission Induction | 1 | 1992 | 3569 | 0.000 |
Why?
|
| Recurrence | 1 | 1992 | 4758 | 0.000 |
Why?
|
| Chemistry, Physical | 1 | 1982 | 39 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1982 | 137 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1982 | 549 | 0.000 |
Why?
|
| Peptide Hydrolases | 1 | 1982 | 256 | 0.000 |
Why?
|
| Texas | 1 | 1992 | 6311 | 0.000 |
Why?
|
| Terminology as Topic | 1 | 1982 | 414 | 0.000 |
Why?
|
| Absorption | 1 | 1979 | 81 | 0.000 |
Why?
|
| Potassium Chloride | 1 | 1979 | 55 | 0.000 |
Why?
|
| Solubility | 1 | 1979 | 242 | 0.000 |
Why?
|
| Karyotyping | 1 | 1980 | 1022 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1979 | 334 | 0.000 |
Why?
|
| Histones | 1 | 1985 | 1466 | 0.000 |
Why?
|
| Rabbits | 1 | 1979 | 957 | 0.000 |
Why?
|
| Insulin | 1 | 1982 | 1454 | 0.000 |
Why?
|
| Aged | 1 | 1992 | 70117 | 0.000 |
Why?
|